Guideline Recommendations for the Management of Non‑Infectious Aortitis

Initial Diagnostic and Therapeutic Approach

Start high‑dose glucocorticoids (prednisone 40–60 mg daily) immediately after aortitis diagnosis and add a steroid‑sparing immunosuppressant—tocilizumab for giant cell arteritis (GCA) or methotrexate for Takayasu arteritis (TAK) and isolated aortitis—to achieve remission and reduce vascular complications. (American College of Rheumatology) [1][2]
Classify large‑vessel vasculitis by age and clinical features: GCA is typical in patients > 50 years with cranial symptoms (headache, jaw claudication, visual changes); TAK usually presents in patients < 40 years with limb claudication and constitutional symptoms. (American College of Rheumatology) 1

Prescribe prednisone 40–60 mg daily (≈ 0.7 mg/kg/day) at disease onset for both GCA‑associated aortitis and TAK. (American College of Rheumatology) [1][2]

Tocilizumab is the preferred adjunctive agent for GCA patients with aortitis, refractory or relapsing disease, or high risk of glucocorticoid‑related adverse events. (American College of Rheumatology) [1][2]
Methotrexate can be used as an alternative steroid‑sparing agent in GCA when tocilizumab is unavailable or contraindicated. (American College of Rheumatology) 2
For all TAK patients, initiate methotrexate together with high‑dose glucocorticoids as first‑line combination therapy. (American College of Rheumatology) [1][2]
Reserve biological therapy (tocilizumab) for TAK patients who are refractory to or experience relapse despite initial glucocorticoid‑methotrexate therapy. (American College of Rheumatology) 2

Do not prescribe routine antiplatelet or anticoagulant therapy solely for large‑vessel vasculitis unless there is an independent cardiovascular indication. (American College of Rheumatology) 2

Critical arterial stenosis causing end‑organ ischemia warrants surgical or endovascular revascularization. (American College of Rheumatology) 2

Continue therapy for non‑infectious aortitis for more than 12–24 months, tapering glucocorticoids gradually based on clinical response, inflammatory marker trends, and serial imaging findings. (American College of Rheumatology) [1][2]

Clinicians should assess patients with newly identified aortitis for giant cell arteritis (typically > 50 years) and Takayasu arteritis (typically < 40 years) by evaluating cranial symptoms, constitutional manifestations, and limb claudication to differentiate systemic large‑vessel vasculitis from isolated disease. 3
Screening for IgG4‑related disease and other systemic inflammatory conditions is recommended as part of the initial evaluation of isolated aortitis. 3

Immunosuppression may be considered only in isolated aortitis patients who demonstrate persistently elevated inflammatory markers (ESR/CRP), progressive vascular lesions on imaging, clinical symptoms suggestive of active inflammation, or high‑risk features such as young age or extensive aortic involvement. 4
When treatment is indicated, the regimen should begin with glucocorticoids (prednisone 40–60 mg daily) combined with methotrexate as a steroid‑sparing agent, following the large‑vessel vasculitis therapeutic paradigm. 3

Clinicians should avoid escalating immunosuppressive therapy solely on the basis of isolated ESR or CRP elevation; infection must be excluded first, and repeat imaging should be performed to confirm disease progression before modifying therapy. 4